Reporter, FDA and drug pricing rules
Celine Castronuovo is a reporter for Bloomberg Law, specializing in FDA and drug pricing rules. She has previously worked for The Hill, Voice of America News, and SMPAGWU. Her articles cover a range of topics including pharmaceutical lawsuits, Medicare drug pricing, and state drug pricing boards.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Celine's coverage is heavily focused on legal and government announcements related to healthcare, pharmaceuticals, drug pricing, and Medicare. She consistently reports on legal actions and regulatory developments within the healthcare sector. Therefore, she would likely be receptive to pitches that provide expert analysis or commentary on ongoing lawsuits, government policies impacting drug pricing or Medicare, and regulatory changes affecting the pharmaceutical industry.
Given her focus on specific legal cases and governmental decisions in the healthcare space, Celine may find value in receiving insights from experts with direct knowledge of these issues or those who can contextualize broader trends in health policy and regulation.
While Celine does not have a specified geographic focus, she provides comprehensive coverage of national-level developments within the United States across various states.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Celine Castronuovo
The Biden administration on Tuesday secured a win in litigation over Medicare’s drug price negotiation program by persuading a federal judge to rule on its motion to dismiss the lawsuit from a leading pharmaceutical industry group.
A disagreement about whether AbbVie Inc. is legally required to negotiate lower prices with Medicare dominated oral arguments Friday on the Biden administration’s motion to dismiss a lawsuit from the US Chamber of Commerce and some of its state affiliates.
The threat of a massive tax is enough to push drugmakers such as Boehringer Ingelheim Pharmaceuticals, Inc. and Novartis AG to comply with the Biden administration’s landmark drug pricing law and negotiate with Medicare.
Infusion therapy providers would be harmed if a federal judge dismisses a lawsuit challenging Medicare’s new drug price negotiation program, attorneys for a coalition of trade associations wrote in a filing Monday.
By: Celine Castronuovo
The FDA would have clear authority to regulate medical tests that come from a single laboratory under a proposal released by the agency Friday.
The Medicare agency may continue implementing its drug price negotiation program even as litigation over the plans play out in federal court, a judge ordered Friday.
By: Celine Castronuovo, Nyah Phengsitthy
Drugmaker Johnson & Johnson has agreed to negotiate drug prices with Medicare for its drugs Xarelto and Stelara, the company told Bloomberg Law Monday.
The Medicare agency must withdraw a Trump-era rule on copay assistance programs under a federal judge’s order following claims from drug industry-backed patient groups that the policy has allowed health plans to increase out-of-pocket prescription drug costs for consumers.
By: Celine Castronuovo
The state of Hawaii has joined the legal fray against the country’s top companies managing prescription drug benefits, alleging the entities are driving up high drug costs for patients they’re supposed to serve.
By: Celine Castronuovo
A wave of state boards aiming to set limits on what health plans pay for prescription drugs is likely to trigger lawsuits from drugmakers, policy analysts and lobbying groups say, as the industry also fights government price-setting policy at the federal level.
(833) 317-6278 
